Government,
Health Care & Hospital Law
Jul. 5, 2023
WILL THE INFLATION REDUCTION ACT SPELL THE END OF HATCH-WAXMAN LITIGATION?
See more on WILL THE INFLATION REDUCTION ACT SPELL THE END OF HATCH-WAXMAN LITIGATION?
The Inflation Reduction Act of 2022 (IRA) has received a lot of attention concerning its potential effect on everything from IRS funding to clean energy. But one aspect of the IRA that has caused much discussion among pharmaceutical companies is the “Price Negotiation Program.” Under this program, drugs approved under new drug applications (NDAs), including “small molecule” (chemically synthesized) drugs, are eligible for selection for “negotiation” (i.e., price setti...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In